Outset Medical (NASDAQ:OM) Issues Quarterly Earnings Results

Outset Medical (NASDAQ:OM - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04), Zacks reports. Outset Medical had a negative net margin of 112.57% and a negative return on equity of 175.64%. The firm had revenue of $29.47 million during the quarter, compared to analysts' expectations of $28.47 million. Outset Medical updated its FY 2025 guidance to EPS.

Outset Medical Trading Down 8.8 %

NASDAQ OM traded down $0.08 during trading hours on Friday, reaching $0.88. The company had a trading volume of 696,815 shares, compared to its average volume of 1,430,621. The stock has a 50-day moving average of $0.95 and a 200 day moving average of $0.83. Outset Medical has a 1-year low of $0.44 and a 1-year high of $5.22. The company has a current ratio of 6.49, a quick ratio of 5.04 and a debt-to-equity ratio of 4.12. The stock has a market capitalization of $47.01 million, a P/E ratio of -0.35 and a beta of 2.01.

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $3.00 target price on shares of Outset Medical in a research report on Tuesday, January 7th.

Insider Transactions at Outset Medical

In other news, CEO Leslie Trigg sold 65,236 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $0.80, for a total transaction of $52,188.80. Following the sale, the chief executive officer now owns 895,580 shares of the company's stock, valued at approximately $716,464. This represents a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel John L. Brottem sold 32,930 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $0.80, for a total transaction of $26,344.00. Following the sale, the general counsel now directly owns 181,188 shares in the company, valued at $144,950.40. This represents a 15.38 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 292,750 shares of company stock valued at $244,707. 4.10% of the stock is currently owned by corporate insiders.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.